|
Virus-Targeted Therapy for Malignancies
|
1R43CA153474-01A1
|
$288,895
|
$144,448
|
PERRINE, SUSAN
|
PHOENICIA BIOSCIENCES, INC.
|
|
Veterans Administration hospitalization database, Patient Treatment File, and Out
|
ZIA CP010126-00580
|
$48,591
|
$2,429
|
McGlynn, Katherine
|
DCEG (NCI)
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S1
|
$74,970
|
$750
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-38S2
|
$139,926
|
$1,399
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-38
|
$4,555,705
|
$45,557
|
WILDING, GEORGE
|
UNIVERSITY OF WISCONSIN MADISON
|
|
UT M.D. Anderson Cancer Center Lymphoma SPORE
|
5P50CA136411-03
|
$475,000
|
$109,250
|
YOUNES, ANAS
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Rochester Cancer Center CCOP Research Base
|
5U10CA037420-27
|
$2,137,632
|
$21,376
|
Morrow, Gary
|
UNIVERSITY OF ROCHESTER
|
|
University of Colorado Southwest Oncology Group
|
5U10CA042777-24
|
|
$0
|
ELIAS, ANTHONY
|
UNIVERSITY OF COLORADO DENVER
|
|
Understanding T Cell Rapamycin Resistance
|
ZIA BC 011220
|
$218,895
|
$21,889
|
Fowler, Daniel
|
CCR (NCI)
|
|
U10 Full Member Application Affiliated with SWOG
|
5U10CA105409-08
|
$325,684
|
$3,257
|
Kim, Edward
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Tumor-Infiltrating Donor Derived Lymphocyte Therapy After Allogeneic Transplant
|
ZIC BC 011029
|
$183,451
|
$73,380
|
Hakim, Frances
|
CCR (NCI)
|
|
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
|
5R01CA098285-08
|
$490,125
|
$490,125
|
ALT, FREDERICK
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
To establish the BC Cancer Agency - Vancouver Centre as a major SWOG centre
|
5U10CA142559-02
|
$188,304
|
$1,883
|
BLANKE, CHARLES
|
BRITISH COLUMBIA CANCER AGENCY
|
|
The Role of Fbxw7 in genetic instability and cancer
|
5R01CA116481-05
|
$345,303
|
$69,061
|
Mao, Jian-Hua
|
UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S1
|
$72,130
|
$721
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-18S2
|
$75,000
|
$750
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-18
|
$4,829,858
|
$48,299
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
TAS::75 0849::TAS INCREMENTAL FUNDING
|
N01CO800001-038
|
$221,493,424
|
$6,219
|
HEIMBROOK, DAVID
|
SAIC-FREDERICK, INC.
|
|
Survivorship: Mentoring and Bridging Primary Care and Oncology
|
1K05CA160724-01
|
$164,278
|
$82,139
|
Oeffinger, Kevin
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
|
3U24CA114766-05S2
|
$378,516
|
$37,852
|
Ramirez, Nilsa
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB)
|
2U24CA114766-06
|
$817,102
|
$81,710
|
RAMIREZ, NILSA
|
NATIONAL CHILDHOOD CANCER FOUNDATION
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$370,199
|
$92,549
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Study of Structures of CCR5 and Its Interactions with CCR5 Inhibitors
|
ZIA BC 011109
|
$73,351
|
$14,670
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
Study of HIV Protease Dimerization (PD) and Identification of PD Inhibitors
|
ZIA BC 011105
|
$146,702
|
$1,467
|
Mitsuya, Hiroaki
|
CCR (NCI)
|
|
Studies of Epstein-Barr Virus
|
5R37CA012055-39
|
$446,398
|
$111,600
|
MILLER, I.
|
YALE UNIVERSITY
|
|
Statins & Lymphoid Malignancy Risk in a Large Multi-Site Population-Based Cohort
|
5R01CA140754-02
|
$574,828
|
$287,414
|
Johnson, Christine C
|
HENRY FORD HEALTH SYSTEM
|
|
Stanford University Cancer Center
|
3P30CA124435-05S1
|
$74,525
|
$745
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
Stanford University Cancer Center
|
5P30CA124435-05
|
$3,091,618
|
$30,916
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
SPORE in Lymphoma
|
5P50CA126752-05
|
$2,153,287
|
$602,920
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
Southwest Oncology Group/University of California, Davis
|
5U10CA046441-24
|
$325,239
|
$3,252
|
GANDARA, DAVID
|
UNIVERSITY OF CALIFORNIA DAVIS
|
|
Southwest Oncology Group U10 Member Site
|
5U10CA014028-38
|
$349,566
|
$3,496
|
FLAHERTY, LAWRENCE
|
WAYNE STATE UNIVERSITY
|
|
Southwest Oncology Group Treatment Grant
|
3U10CA032102-32S1
|
$665,444
|
$6,654
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Southwest Oncology Group Treatment Grant
|
5U10CA032102-32
|
$8,893,886
|
$88,939
|
BAKER, LAURENCE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER
|
5U10CA038926-26
|
$4,603,957
|
$46,040
|
CROWLEY, JOHN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
SOUTHWEST ONCOLOGY GROUP CA13612
|
5U10CA013612-38
|
$264,593
|
$2,646
|
MILLER, THOMAS
|
UNIVERSITY OF ARIZONA
|
|
Southwest Oncology Group
|
5U10CA046282-24
|
$338,795
|
$3,388
|
STIFF, PATRICK
|
LOYOLA UNIVERSITY CHICAGO
|
|
Southwest Oncology Group
|
5U10CA020319-35
|
$387,405
|
$3,874
|
Rivkin, Saul
|
SWEDISH MEDICAL CENTER, FIRST HILL
|
|
Southwest Oncology Group
|
5U10CA027057-32
|
$422,375
|
$4,224
|
SCHOTT, ANNE
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Southwest Oncology Group
|
5U10CA011083-44
|
$355,653
|
$3,557
|
FRIEDBERG, JONATHAN
|
UNIVERSITY OF ROCHESTER
|
|
Southwest Oncology Group
|
5U10CA058882-19
|
$337,375
|
$3,374
|
LENZ, HEINZ JOSEF
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
South Texas Pediatric Minority Based CCOP
|
3U10CA052771-21S1
|
$50,000
|
$500
|
LANGEVIN, ANNE-MARIE
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
South Texas Pediatric Minority Based CCOP
|
5U10CA052771-21
|
$321,790
|
$3,218
|
LANGEVIN, ANNE-MARIE
|
UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT
|
|
Signal Transduction Pathways in CD30-positive Lymphomas
|
5R01CA142809-02
|
$309,234
|
$154,617
|
DUCKETT, COLIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Signal transduction inhibitor therapy for Lymphoma
|
5R01CA127433-05
|
$325,779
|
$162,890
|
Witzig, Thomas
|
MAYO CLINIC
|
|
RF Analysis of hematopoietic malignancies in various radiotherapeutically irradia
|
ZIA CP010131-10595
|
$78,845
|
$15,769
|
Little, Mark
|
DCEG (NCI)
|
|
Research Management and Support
|
RMS2011 [E]
|
$335,240,650
|
$245,990
|
N/A
|
National Cancer Institute
|
|
Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$55,940
|
$11,188
|
Bishop, Michael
|
CCR (NCI)
|
|
Regulation of RANTES expression in T lymphocytes
|
ZIA BC 011025
|
$643,825
|
$128,765
|
Krensky, Alan
|
CCR (NCI)
|
|
Regulation of Exocytosis from Immune Cells
|
ZIA BC 011035
|
$252,293
|
$63,073
|
Roche, Paul
|
CCR (NCI)
|
|
Regulation of Epstein-Barr Virus Latency
|
5R01CA093606-09
|
$294,182
|
$235,346
|
LIEBERMAN, PAUL
|
WISTAR INSTITUTE
|
Total relevant funding to Hodgkins disease for this search: $13,379,528
|